Skip to main content
Download PDF

The Value of Influenza and Pneumococcal Vaccines in the Elderly

Drugs & Aging volume 8, pages 445–451 (1996)Cite this article

Summary

Influenza and pneumococcal vaccines have been available for decades and have repeatedly been shown to be efficacious in healthy adults. However, for both vaccines, efficacy in high risk populations and older individuals does not seem to be as great, leading to reluctance to use them as recommended. Recent observational studies in older individuals have confirmed and quantified the effectiveness of the 2 vaccines in situations of actual use. Economic data indicate that under realistic situations they are likely to reduce costs for healthcare systems. Societal benefits are now also established. While it may be useful to confirm the cost savings in additional systems of healthcare, the current emphasis should be to devise strategies to increase use of the vaccines.

References

  1. Serfling RE, Sherman IL, Housworth WJ. Excess pneumonia-influenza mortality by age and sex in three major influenza A2 epidemics, United States, 1957–58, 1960, and 1963. Am J Epidemiol 1967; 86: 433–41

    PubMed  CAS  Google Scholar 

  2. Fiebach N, Beckett W. Prevention of respiratory infections in adults: influenza and pneumococcal vaccines. Arch Intern Med 1994; 154: 2545–57

    PubMed  Article  CAS  Google Scholar 

  3. Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. PharmacoEconomics 1992; 2: 198–206

    PubMed  Article  CAS  Google Scholar 

  4. Butler JC, Brieman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations. JAMA 1993; 270: 1826–31

    PubMed  Article  CAS  Google Scholar 

  5. Strassburg MA, Greenland S, Sorvillo FJ, et al. Influenza in the elderly: report of an outbreak and a review of vaccine effectiveness reports. Vaccine 1986; 4: 38–44

    PubMed  Article  CAS  Google Scholar 

  6. Coles FB, Balzano GJ, Morse DL. An outbreak of influenza A(H3N2) in a well immunized nursing home population. J Am Geriatr Soc 1992; 40: 589–92

    PubMed  CAS  Google Scholar 

  7. Phair J, Kauffman CA, Bjornson A, et al. Failure to respond to influenza vaccine in the aged: correlation with B-cell number and function. J Lab Clin Med 1978; 92: 822–8

    PubMed  CAS  Google Scholar 

  8. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illnesses and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253: 1136–9

    PubMed  Article  CAS  Google Scholar 

  9. Office of Technology Assessment, US Congress. Cost effectiveness of influenza vaccination. Washington, DC: Government Printing Office, 1982

    Google Scholar 

  10. Meitl JF. Influenza immunization for Medicare eligibles: a demonstration of cost-effectiveness. Twenty-second Immunization Conference Proceedings. Atlanta (GA): United States Department of Health and Human Services, Public Health Services, 1988: 117–8

    Google Scholar 

  11. McBean AM, Babish JD, Warren JL. The impact and cost of influenza in the elderly. Arch Intern Med 1993; 153: 2105–11

    PubMed  Article  CAS  Google Scholar 

  12. Foster DA, Talsma A, Furumoto-Dawson A, et al. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. Am J Epidemiol 1992; 136: 296–307

    PubMed  CAS  Google Scholar 

  13. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. Int J Epidemiol 1995; 24: 1240–8

    PubMed  Article  CAS  Google Scholar 

  14. Centers for Disease Control. Final results: Medicare influenza vaccine demonstration — selected states, 1988–1992. MMWR Morbid Mortal Wkly Rep 1993; 42: 601–4

    Google Scholar 

  15. Fedson DS, Wajda A, Nicol JP, et al. Clinical effectiveness of influenza vaccine in Manitoba. JAMA 1993; 270: 1956–61

    PubMed  Article  CAS  Google Scholar 

  16. Nichol KL, Margolis KL, Wuorenma H, et al. The efficacy and cost-effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994; 331: 778–84

    PubMed  Article  CAS  Google Scholar 

  17. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121: 947–52

    PubMed  CAS  Google Scholar 

  18. Mucher DM, Watson DA, Dominguez EA. Pneumococcal vaccination: work to date and future prospects. Am J Med Sci 1990; 300: 45–52

    Article  Google Scholar 

  19. Heffron R. Pneumonia with special reference to pneumococcus lobar pneumonia. New York: The Commonwealth Fund, 1939: 446–78

    Google Scholar 

  20. Fedson DS, Wajda A, Nicol JP, et al. The old man’s friend [letter]. Lancet 1993; 342: 561

    PubMed  Article  CAS  Google Scholar 

  21. Austrian R, Douglas RM, Schiffman G, et al. Prevention of pneumonia by vaccination. Trans Assoc Am Phys 1976; 89: 184–94

    PubMed  CAS  Google Scholar 

  22. Kerttula Y, Leinonen M, Koskela M, et al. The aetiology of pneumonia: application of bacterial serology and basic laboratory methods. J Infect 1987; 14: 21–30

    PubMed  Article  CAS  Google Scholar 

  23. Austrian R. A reassessment of pneumococcal vaccine. N Engl Med 1984; 310: 651–3

    Article  CAS  Google Scholar 

  24. Clemens JD, Shapiro ED. Resolving the pneumococcal vaccine controversy: are there alternatives to randomized clinical trials? Rev Infect Dis 1984; 6: 589–99

    PubMed  Article  CAS  Google Scholar 

  25. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453–60

    PubMed  Article  CAS  Google Scholar 

  26. LaForce FM, Eickhoff TC. Pneumococcal vaccine: an emerging consensus. Ann Intern Med 1988; 108: 757–9

    PubMed  CAS  Google Scholar 

  27. Forrester HL, Jahnigen DW, LaForce FM. Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 1987; 83: 425–30

    PubMed  Article  CAS  Google Scholar 

  28. Borgono JM, McLean AA, Vell PP, et al. Vaccination and revaccination with polyvalent pneumococcal polysaccharide vaccines in adults and infants. Proc Soc Exp Biol Med 1978; 157: 148–54

    PubMed  CAS  Google Scholar 

  29. Centers for Disease Control and Prevention. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989; 38: 64–76

    Google Scholar 

  30. Sisk JF, Riegelman RK. Cost effectiveness of vaccination against pneumococcal pneumonia: an update. Ann Intern Med 1986; 104: 79–86

    PubMed  CAS  Google Scholar 

  31. McBean AM, Babish JD, Prihoda R. The utilization of pneumococcal polysaccharide vaccine among elderly Medicare beneficiaries, 1985 through 1988. Arch Intern Med 1991; 151: 2009–16

    PubMed  Article  CAS  Google Scholar 

  32. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine: efficacy and associated cost savings. JAMA 1990; 264: 2910–5

    PubMed  Article  CAS  Google Scholar 

  33. DeStefano F, Goodman RT, Noble GR, et al. Simultaneous administration of influenza and pneumococcal vaccine. JAMA 1982; 247: 2551–4

    Article  Google Scholar 

  34. Applebaum PC. Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clin Infect Dis 1992; 15: 77–83

    Article  Google Scholar 

Download references

Author information

Affiliations

  1. School of Public Health, University of Michigan, 109 Observatory, Ann Arbor, Michigan, 48109, USA

    Arnold S. Monto

  2. Department of Internal Medicine, Division of Geriatric Medicine, Department of Veterans Affairs Hospital, University of Michigan, Ann Arbor, Michigan, USA

    Margaret S. Terpenning

Authors
  1. Arnold S. Monto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Margaret S. Terpenning
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Monto, A.S., Terpenning, M.S. The Value of Influenza and Pneumococcal Vaccines in the Elderly. Drugs & Aging 8, 445–451 (1996). https://doi.org/10.2165/00002512-199608060-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199608060-00006

Keywords

  • Influenza
  • Adis International Limited
  • Influenza Vaccine
  • Pneumococcal Vaccine
  • Pneumococcal Pneumonia